Johnson & Johnson (JNJ) Tops Q3 EPS by 2c, Updates FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Johnson & Johnson (JNJ) PT Raised to $150 at RBC Capital
October 17, 2018 7:49 AM EDTRBC Capital analyst Glenn Novarro raised the price target on Johnson & Johnson (NYSE: JNJ) to $150.00 (from $143.00) while maintaining an Outperform rating following Q3 results.
Novarro notes Pharma excelled again, and the Devices & Consumer segments are heading in the right direction.
The... More
